{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:27Z","timestamp":1790983167216,"version":"4.1.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Voriconazole, a first-line therapy for invasive aspergillosis, exhibits variable pharmacokinetics due to\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      polymorphisms. However, severe hematological toxicity, particularly life-threatening neutropenia, remains under-recognized. The concomitant occurrence of dual severe organ toxicities in CYP2C19 poor metabolizers (PMs) poses a significant clinical challenge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>\n                      We report a case of a 71-year-old Chinese male with invasive pulmonary aspergillosis. After approximately 40 days of oral voriconazole therapy (400\u00a0mg q12h loading dose, then 200\u00a0mg q12h maintenance), he sequentially developed grade 4 neutropenia (Absolute Neutrophil Count nadir 0.02 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L) with fever and grade 3 hepatocellular liver injury (Alanine Aminotransferase [ALT] peak 738 U\/L; R ratio approximately 65.9). Pharmacogenomic testing performed during hospitalization on 27 March 2025 revealed a\n                      <jats:italic>CYP2C19 *2\/*3<\/jats:italic>\n                      PM genotype. Causality assessments using the Naranjo and RUCAM scales rated both events as probable in relation to voriconazole. Following discontinuation of voriconazole, antifungal therapy was sequentially changed to isavuconazonium sulfate, nebulized amphotericin B liposome, and intravenous amphotericin B cholesteryl sulfate complex, together with granulocyte colony-stimulating factor and hepatoprotective therapy. The patient\u2019s neutrophil count and liver function improved, and he was discharged in stable condition with isavuconazonium sulfate capsules 200\u00a0mg qd after discharge. After discharge, he reported feeling well but did not undergo follow-up laboratory or imaging examinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This case illustrates a clinical scenario in which pre-emptive pharmacogenomic testing, vigilant monitoring of complete blood counts alongside liver function, and integration with therapeutic drug monitoring (TDM) may enhance safety in patients requiring long-term voriconazole therapy. The absence of TDM data precludes definitive confirmation of voriconazole overexposure; nevertheless, the convergence of\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      PM genotype, temporal relationship, dechallenge, and structured causality assessment renders presumed drug accumulation the most plausible explanation for the observed toxicities while not excluding all competing contributors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1875506","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:37:29Z","timestamp":1787290649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Dual toxicity of voriconazole in a CYP2C19 poor metabolizer: a case analysis of life-threatening neutropenia and hepatocellular injury"],"prefix":"10.3389","volume":"17","author":[{"given":"Ke-Ke","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huaihe Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Department of Pharmacy, Union Hospital Tongji Medical College Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jing","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital Tongji Medical College Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic-pharmacokinetic prospective multicenter study","volume":"40","author":"Blanco-Dorado","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological Society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/FPC.0000000000000536","article-title":"Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients","volume":"34","author":"Du","year":"2024","journal-title":"Pharmacogenet Genomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"105871","DOI":"10.1016\/j.yrtph.2025.105871","article-title":"Mechanism and marker of voriconazole-induced liver injury: insights from a quantitative systems toxicology approach","volume":"162","author":"Du","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1164\/rccm.202410-2045ST","article-title":"Treatment of invasive pulmonary aspergillosis and preventive and empirical therapy for invasive candidiasis in adult pulmonary and critical care patients: an official American Thoracic Society Clinical Practice Guideline","volume":"211","author":"Epelbaum","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.2147\/IDR.S419382","article-title":"Voriconazole-induced hepatotoxicity in a patient with pulmonary aspergillosis: a case report","volume":"16","author":"Gu","year":"2023","journal-title":"Infect. Drug Resist"},{"key":"B16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/toxsci\/kfx029","article-title":"Hepatocellular toxicity of imidazole and triazole antimycotic agents","volume":"157","author":"Haegler","year":"2017","journal-title":"Toxicol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Johnston","year":"2015","journal-title":"Expert Opin Drug Metab. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70317","DOI":"10.1111\/cts.70317","article-title":"CYP2C19-Guided voriconazole therapy: a precision medicine approach to mitigate adverse effects in Japanese patients","volume":"18","author":"Katada","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0048725","DOI":"10.1128\/aac.00487-25","article-title":"Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort","volume":"69","author":"Lou","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1109\/EMBC40787.2023.10340343","article-title":"The investigation and prediction of voriconazole-associated hepatotoxicity under therapeutic drug monitoring","volume":"2023","author":"Ma","year":"2023","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/j.1552-4604.1992.tb04635.x","article-title":"Advances in the diagnosis of adverse drug reactions","volume":"32","author":"Naranjo","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1875506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:37:35Z","timestamp":1787290655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1875506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":17,"alternative-id":["10.3389\/fphar.2026.1875506"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1875506","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1875506"}}